<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="TB2" orientation="portrait" position="float">
 <label>TABLE 2</label>
 <caption>
  <p>Drug interactions between tuberculosis (TB) and potential COVID-19 medications</p>
 </caption>
 <table frame="hsides" rules="groups">
  <colgroup span="1">
   <col align="left" span="1"/>
  </colgroup>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <graphic xlink:href="ERJ-01727-2020.03" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <graphic xlink:href="ERJ-01727-2020.04" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>WHO: World Health Organization; INH: isoniazid; RIF: rifampicin; EMB: ethambutol; PZA: pyrazinamide; LFX: levofloxacin; MFX: moxifloxacin; BDQ: bedaquiline; LZD: linezolid; CFZ: clofazimine; Cs: cycloserine; DLM: delamanid; IMI/CIS: imipenem/cilastin; MEM: meropenem; AMI: amikacin; STR: streptomycin; ETO: ethionamide; PTO: prothionamide; PAS: 
   <italic>p-</italic>aminosalicylic acid; CYP: cytochrome P450; UGT: UDP glucuronosyltransferase. 
   <sup>#</sup>: recommended based on predicted interaction; 
   <sup>¶</sup>: UGT 1A1 is involved in moxifloxacin metabolism and could be involved in umifenovir metabolism (mainly UGT 1A9); 
   <sup>+</sup>: both drugs are metabolised by CYP3A4; 
   <sup>§</sup>: CYP3A4 is involved in the metabolism of baloxavir (minor extent) and umifenovir, and clofazimine is a CYP3A4 inhibitor; 
   <sup>ƒ</sup>: both drugs primarily undergo renal excretion.
  </p>
 </table-wrap-foot>
</table-wrap>
